Peripheral Vascular Disease

This registry study, called PEripheral Use of AngioJet® Rheolytic Thrombectomy With a Variety of Catheter Lengths (PEARL II), involves the collection of information for research and educational purposes only on the use of AngioJet® in the peripheral vascular system.

The purpose of this study is to:

• Estimate the rate of AngioJet® System related adverse events
• Estimate the change in degree of occlusion from Baseline to Final angiogram
• Estimate the proportion of successful patients post-procedure and those affected by restenosis and /or rethrombosis of the treated vessels throughout a 12 month follow-up

A total of 500 patients will participate in this study from approximately 24 centers. This study involves both venous and arterial system occlusions. The Reading Hospital is currently enrolling patients in the PEARL II study, which is expected to remain open until January 2013.

For more information, please call the Clinical Trials Office at 610-988-4308 or visit clinicaltrials.gov.